Category
162 articles — page 5 of 14
The timeline for judging whether Opzelura is working is longer than most people expect, and stopping too early is one of the most common reasons it gets written off unfairly. Here's a realistic framework.
Winter changes the vitiligo care equation — less sun, drier skin, more indoor heating. Here's how to adjust your routine for the season.
Incyte's povorcitinib met its Phase 3 endpoints in May 2026 — another oral JAK1/TYK2 inhibitor joining upadacitinib and ritlecitinib in the race for systemic vitiligo treatment. Here is what it is and what it means for patients now.
Teva paid Royalty Pharma $500 million for TEV-53408, an anti-IL-15 antibody now in Phase 1b trials for vitiligo. Unlike JAK inhibitors, it targets the memory T cells responsible for relapse — meaning it may allow remission to last after treatment stops.
If a dermatologist told you nothing can be done about your vitiligo, that is not the end of the conversation — it is a sign to ask someone else. Here are the red flags, the questions to ask, and where to find a specialist who treats vitiligo actively.
The three to six months after delivery are the highest-risk window for vitiligo flares — more so than pregnancy itself. Here is why the postpartum immune shift triggers spreading, and what you can do about it while breastfeeding.
Ritlecitinib is an oral JAK3/TEC inhibitor — the first oral JAK pill to complete Phase 3 trials specifically for vitiligo. Here is what it is, how it works, how it compares to Opzelura, and who it is likely to help.
Knowing whether your vitiligo is actively spreading — versus stable — changes what you should do next. Here is how to tell the difference, what active disease looks like, and what the evidence says about stopping it.
Stress is often linked to vitiligo flares. But what does the research actually say about meditation and stress reduction as part of vitiligo management? An honest look at the evidence.
World Vitiligo Day 2026 falls at a genuinely significant moment for treatment. An oral JAK inhibitor is awaiting FDA approval, a second has Phase 3 wins, NHS patients can now access Opzelura, and a new Phase 3 study confirmed baricitinib efficacy. Here is what is real and what it means.
Afamelanotide is a synthetic melanocortin analogue approved in Europe for a different condition, but studied as a phototherapy enhancer in vitiligo. The data shows meaningful benefit when combined with NbUVB. Here is what we know.
Alpha lipoic acid has been studied in combination with phototherapy for vitiligo in small trials showing modest benefit. Here is what the evidence actually says and where it fits in a rational treatment plan.
